LISATA THERAPEUTICS, INC. 8-K

What Happened
Lisata Therapeutics, Inc. (LSTA) announced it entered into an Agreement and Plan of Merger dated March 6, 2026 with Kuva Labs Inc. (Parent) and Kuva Acquisition Corp. (Purchaser). Purchaser will commence a tender offer to buy all outstanding common shares for $5.00 per share in cash plus one non-transferable contingent value right (CVR). The CVR would pay $1.00 if a New Drug Application (NDA) or similar filing/acceptance is made for the product candidate known as “certepetide” (alone or in combination) before the earlier of (a) the seventh anniversary of closing and (b) termination of the CVR Agreement. The Company filed the 8‑K on March 9, 2026 and issued a press release on March 6, 2026.

Key Details

• Offer Price: $5.00 cash per common share (net to seller, subject to withholding) plus one CVR potentially worth $1.00 if the specified regulatory milestone for certepetide is met.
• Milestone & CVR terms: CVRs are non-tradable contractual rights, non-voting, and payable only if the NDA/registration milestone is filed/accepted by a regulatory authority within the milestone window (up to 7 years); Parent must use “commercially reasonable efforts” to achieve the Milestone.
• Closing mechanics & conditions: Purchaser’s offer requires valid tenders (not withdrawn) representing a majority of outstanding shares (including certain rollover shares) to satisfy the Minimum Tender Condition; the Merger may be completed under DGCL §251(h) without a shareholder vote if the Offer is successful. The transaction is not subject to a financing condition; Parent delivered a capital commitment letter dated March 3, 2026.
• Corporate actions & compensation treatment: In‑the‑money options, restricted stock and RSUs will vest and be cancelled for cash equal to the spread or Closing Amount plus one CVR per share where applicable; out‑of‑the‑money options will be cancelled without payment. The Company Board unanimously approved the Merger Agreement and recommends shareholders tender their shares.
• Termination fee: $2,000,000 payable by the Company (or payable by Parent in specified circumstances) under defined termination scenarios.

Why It Matters

• Immediate cash liquidity: Common shareholders who tender will receive $5.00 per share in cash at closing, providing a clear near‑term cash exit.
• Upside is limited and conditional: Holders also receive a single CVR that could pay $1.00 only if the specified regulatory milestone for certepetide is achieved within the limited window; the CVR is non-tradable and subject to development and regulatory risk.
• Effect on equity holders: Stock options, RSUs and restricted shares are accelerated and converted into cash and CVRs per the agreement, so unvested awards will generally be cashed out rather than retained as equity.
• Deal mechanics reduce certain risks: The offer is not conditioned on financing and includes a capital commitment letter, which may lower the risk that the buyer cannot fund the cash portion; however, the Minimum Tender Condition (majority of shares) must be met for the transaction to close without a stockholder vote.

For full legal terms, vesting/payment mechanics, and the CVR form, see the Merger Agreement and CVR Agreement filed as exhibits to the 8‑K.